Adjunctive pharmacotherapy for stabilizing @entity1 with @entity1187 /non-ST-segment elevation @entity583 (ACS/NSTEMI) and for subsequent percutaneous coronary intervention (PCI) includes a combination of anticoagulant and antiplatelet agents. However, all anticoagulants have been shown to paradoxically activate platelets and induce other prothrombotic activities, increase @entity548 , and/or cause @entity882 . A single-center experience of 1,400 consecutive @entity1 presenting with ACS/NSTEMI managed using decreased-dose anticoagulation (enoxaparin) and dual-antiplatelet therapy ( @entity117 and @entity1397 ) followed by triple-antiplatelet therapy ( @entity117 , @entity1397 , and eptifibatide) alone, without additional anticoagulation, during subsequent PCI was retrospectively analyzed. @entity1 received a median of 3 doses of enoxaparin at a mean dose of 0.51 mg/kg. The final dose was administered 10.8 hours (mean) before PCI. Medical management "failed" in 8 @entity1 (0.6%), and each required emergency PCI. The overall technical success rate was 99.8%. One major adverse clinical event (0.1%) occurred within 24 hours after PCI. Non-Q-wave @entity583 occurred in 1.8% of @entity1 , major and minor @entity548 complications, in 0.1% and 2.1%, respectively, and @entity882 in 1.3%. Five additional major adverse clinical events (0.4%) occurred within 30 days after PCI, none involving target vessel @entity715 . In conclusion, for @entity1 with ACS/NSTEMI, reduced-dose enoxaparin combined with dual-antiplatelet therapy followed by triple-antiplatelet therapy alone (without additional anticoagulation) during subsequent PCI appears safe and may prove efficacious.

Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation XXXX followed by antiplatelet therapy alone for percutaneous coronary intervention.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndrome'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']
@entity1187 :: (MESH:D054058,Disease) :: ['acute coronary syndrome']
